Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases
Figure 1
Serum levels of NGAL and CA19-9 in cholangiocarcinoma and control (benign biliary tract disease) patients. (a) Box plots comparing levels of NGAL and (b) CA19-9 between cholangiocarcinoma and control are illustrated. (c) Box plots comparing levels of NGAL and (d) CA19-9 between early and advanced stages of cholangiocarcinoma and control are illustrated. Levels of NGAL are presented as ng/mL, whereas CA19-9 is presented with the log data to accommodate the wide range. (*; Mann-Whitney U; compared to control, **; Student’s -test; compared to control, ***; Kruskal-Wallis test; compared to control, ****; ANOVA; compared to control).
